Lab
Pathologists Regional Laboratory
Pathologists Regional Laboratory was paid $1.05M by Medicaid between Jan 2018 and Nov 2024, across 67 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 33% of everything it billed.
33Billing provider infoPATHOLOGISTS REGIONAL LABORATORY
LEWISTON, ID 83501
LEWISTON, ID 83501
33aNPI1407893993assigned 06/01/2006
33bProvider typeClinical Medical Laboratory
28Total paid$1.05M
24GClaims75,845
24DCodes billed67
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Idaho
Rank by total paid#4 of 16
Median peer was paid$8K
This provider vs. median138×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,297 | $147K | |
| 2019 | 13,530 | $140K | |
| 2020 | 10,300 | $185K | |
| 2021 | 13,050 | $226K | |
| 2022 | 9,038 | $154K | |
| 2023 | 10,828 | $147K | |
| 2024incomplete | 3,802 | $47K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 33% | 8,649 | 6,200 | $341K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 11% | 4,960 | 4,829 | $120K |
| 88312 | 6.0% | 1,316 | 1,174 | $63K | |
| 88307 | 5.7% | 422 | 382 | $59K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.6% | 1,769 | 1,641 | $48K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.6% | 1,775 | 1,646 | $48K |
| 80053 | Comprehensive metabolic panel | 3.4% | 6,352 | 5,514 | $35K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.1% | 3,463 | 3,237 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 7,042 | 5,929 | $30K |
| 88313 | 2.7% | 857 | 760 | $29K | |
| 36415 | Collection of venous blood by venipuncture | 2.3% | 11,751 | 9,287 | $24K |
| 88141 | 2.1% | 1,118 | 1,082 | $22K |
55 more codes
| 80061 | Lipid panel | 1.8% | 2,529 | $19K |
| 88341 | 1.8% | 170 | $19K | |
| 88342 | 1.5% | 334 | $16K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.3% | 457 | $14K |
| 88304 | 1.3% | 613 | $14K | |
| 87077 | 1.2% | 2,249 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.2% | 2,513 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 198 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 658 | $8K |
| 87186 | <1% | 1,381 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,265 | $6K |
| 86780 | <1% | 535 | $6K | |
| 86850 | <1% | 578 | $4K | |
| 87070 | <1% | 667 | $4K | |
| 86762 | <1% | 300 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 99 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,014 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 159 | $3K |
| 84439 | <1% | 365 | $2K | |
| 88300 | <1% | 194 | $2K | |
| 87625 | <1% | 90 | $2K | |
| 85652 | <1% | 951 | $2K | |
| 82728 | <1% | 203 | $2K | |
| 87081 | <1% | 301 | $2K | |
| 87205 | <1% | 536 | $2K | |
| 81001 | <1% | 1,269 | $2K | |
| 86900 | <1% | 590 | $1K | |
| 86901 | <1% | 589 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 31 | $1K |
| 85007 | <1% | 421 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 133 | $1K |
| 85610 | <1% | 1,441 | $1K | |
| 86140 | <1% | 262 | $925.68 | |
| 86803 | <1% | 92 | $872.43 | |
| 84481 | <1% | 55 | $687.76 | |
| 85027 | <1% | 175 | $683.89 | |
| 80076 | <1% | 98 | $581.51 | |
| 83880 | <1% | 99 | $489.89 | |
| 87340 | <1% | 52 | $372.27 | |
| 83540 | <1% | 103 | $350.66 | |
| 83550 | <1% | 63 | $325.29 | |
| 88142 | <1% | 16 | $270.12 | |
| 82607 | <1% | 34 | $250.25 | |
| 87430 | <1% | 16 | $231.06 | |
| 82570 | <1% | 52 | $175.62 | |
| 82565 | <1% | 36 | $141.07 | |
| 81003 | <1% | 76 | $133.81 | |
| 87210 | <1% | 13 | $116.16 | |
| 80164 | <1% | 15 | $78.62 | |
| 86592 | <1% | 18 | $77.14 | |
| 82043 | <1% | 12 | $37.13 | |
| 83735 | <1% | 12 | $32.68 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 1,937 | $0.00 |
| 99001 | 0% | 246 | $0.00 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAZZARINI, LOU ANN (ADMINISTATIVE SUPERVISOR)